SEC probes Bayer deal as Trius raises $45.2M to advance tedizolid
This article was originally published in Scrip
Executive Summary
Trius Therapeutics is to raise $45.2 million through the sale of 8.6 million shares at $5.25 per share at a 9.3% discount to the company’s trading price of $5.79 on 25 January. The firm is advancing its lead antibiotic which is in Phase III trials, TR701-112 (tedizolid phosphate), for patients with acute bacterial skin and skin structure infections (ABSSSI).